CSOP Coinbase Daily (2x) Leveraged Product(07711.HK) Fell 16.79% to 34.580
Newtimespace News, as of 11:18 on May 18, CSOP Coinbase Daily (2x) Leveraged Product(07711.HK) was quoted at HKD 34.580, down 16.79%. The ETF opened at HKD 35.340, with a high of HKD 35.340 and a low of HKD 33.800. The latest Net Asset Value (NAV) per unit is HKD 36.252, with a premium rate of 14.64%. The asset size is approximately HKD 43.9348 million.
CSOP Coinbase Daily (2x) Leveraged Product(07711.HK) is a leveraged and inverse product issued by CSOP Asset Management Limited. It aims to provide investment returns, before fees and expenses, that closely correspond to twice (2x) the daily performance of Coinbase Global, Inc. (NASDAQ: COIN) ordinary shares. The product achieves this through financial derivatives such as swap contracts and features a daily reset mechanism. It is a high-risk investment product suitable for aggressive investors with extensive experience and clear judgments on short-term market trends for short-term trading.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VIRTUAL MIND (01520.HK): Forms Joint Venture with Gou Si Technology to Expand AI and Continuous Learning Business, Holding 51% Equity
- CIRC (01763.HK): General Manager Zhang Junqi Resigns, Li Penghui Appointed as Successor
- CHONGQING M&E (02722.HK): Wholly-Owned Subsidiary Files for Bankruptcy Liquidation, Court Acceptance Uncertain
- XH NEWS MEDIA (00309.HK): Winding-up Petition Withdrawn as HKD 588,808 Debt Fully Settled
- TONG REN TANG (01666.HK): Subsidiary Obtains Certificate of Registration for Chinese Patent Medicine, Sanzi Yangqin Granules to Be Sold in Hong Kong